ecrin-mdr-crcClinical2012Cancer colorectal metastásico.Metastatic Colorectal CancerColorectal cancer metastaticColorectal cancerColorectal NeoplasmsMetastatic Colorectal CancerColorectal CancerCancer Colorectal Metastásico.Colorectal Cancer MetastaticColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2128557Spain7Irinotecanacido FolínicoFOLFOXIRI5-FluorouraciloCirculating tumor cellFOLFOXoxaliplatinoBevacizumabECRIN MDRCompletedfalseStudy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral CellsThe purpose of the study is to evaluate FOLFOX + bevacizumab versus FOLFOXIRI + bevacizumab as first line treatment of patients with metastatic colorectal cancer not previously treated and with three or more circulating tumoral cells.2012-07-152128557NCT016404052012-000846-37